scores on the BARS (p = 0.07). Conclusion: This study found no significant effect of OXC in treatment of agitation and aggression in patients with dementia.
Introduction
Behavioral and psychological symptoms of dementia are frequent, especially in nursing home populations [1] . Approximately 80% of the patients in Norwegian nursing homes have dementia, and 89% exhibit at least 1 behavioral or psychological symptom [2] . In this and other studies, the prevalence of agitation and aggression was over 20% [3, 4] . These symptoms are clinically important because they put a heavy strain on the caregivers [5, 6] and often lead to excessive use of psychotropic drugs, especially antipsychotics [7] [8] [9] . Antipsychotics have only a modest effect, and patients treated with such drugs run a definite risk of serious and even irreversible side effects [10] . Therefore, treatment with antipsychotics is not an ideal solution to the challenges of behavioral and psychological symptoms of dementia [11] [12] [13] . A review of pharmacological treatment of these dementia symptoms concluded that no treatment may be preferable and the effect sizes have been modest at best [14] . Carbamazepine was efficacious in treating agitation and aggression in 1 study [15] , whereas no effect was found in another study [16] . Studies investigating the efficacy of other antiepileptic drugs, such as valproate [17] [18] [19] and divalproex sodium [20, 21] , have reported conflicting and inconclusive results.
Case reports indicate that oxcarbazepine (OXC) may offer an effective treatment for agitation and aggression in patients with dementia, but no controlled trial has been performed. OXC has a similar structure to carba mazepine, adding an extra oxygen atom. This leads to a different route of metabolization, reducing interactions with other drugs and side effects. Similarly to carba mazepine, OXC inhibits the sodium channels and through this stabilizes the cell membranes. Compared to carba mazepine, OXC has a lower frequency of side effects. The aim of this study was to evaluate whether OXC is efficacious in the treatment of agitation and aggression in institutionalized patients with Alzheimer's disease or vascular dementia.
Methods

Study Setting and Design
This was an 8-week, multicenter, double-blind, randomized, placebo-controlled trial performed independently of the pharmaceutical industry. The pharmaceutical company Novartis donated the drug, but was not involved in the study design, analyses or interpretation of the results. The authors and a protocol committee designed the trial and wrote the protocol (see appendix). Patients were recruited from 35 nursing homes across Norway under the guidance of 15 investigators who were either specialists in geriatric psychiatry or geriatric medicine. Prior to inclusion, the diagnosis of each patient's dementia, mental and physical capacity, and mental health status were assessed. Except for 1 patient who had the capacity to consent to the study himself, the legally authorized representatives of the patients gave written informed consent. For security reasons and to track adverse events, patients were followed up for an additional 4 weeks after the trial medication had been discontinued. The study was approved by the Norwegian state's authorities in charge of regulating research and the Regional Ethics Committee in south Norway.
Patients
The patients included both males (29.1%) and females (70.9%) having been in nursing homes for at least 4 weeks prior to inclusion. They had a median age of 84 years (range: 63-98), and had received a diagnosis of Alzheimer's disease or vascular dementia according to ICD-10 diagnostic criteria for research [22] . We did not differentiate between Alzheimer's disease and vascular dementia, because it is challenging to clearly separate between them in this age group and in the late stages of dementia [23, 24] . In the main, we followed the study design of Tariot et al. [25] to make our study comparable to the only trial using antiepileptics that showed a significant effect. The dementias were of moderate to severe degrees, as defined by a Mini Mental State Examination score of 0-20 [26] , and the patients had a history of agitation or aggression for at least 1 week and a score of 6 6 on the Neuropsychiatric Inventory nursing home version (NPI-NH) subscale for agitation and aggression [27, 28] . Our definition of agitation and aggression was pragmatic: the subscale agitation/aggression of the NPI-NH was used to identify eligible patients. Patients with the following clinical abnormalities were excluded: low sodium serum levels ( ! 135 mmol/l), severely impaired renal function (creatinine clearance ! 30 ml/min, calculated with Cockroft and Gault's formula), or hepatic failure (transaminases ␥ -GT and ALAT three times or more over upper normal limit). Furthermore, patients with the following diseases were excluded: atrioventricular blocks II and III and all kinds of arrhythmia necessitating treatment; severe somatic diseases that might demand a change of medication; severe or acute neurological disease (e.g. epilepsy, acute cerebrovascular events, severe Parkinson's disease, acute confusion) or a severe psychiatric disorder such as bipolar disorder or schizophrenia; dementia other than Alzheimer's disease or vascular dementia. Patients who had participated in another clinical trial during the previous 3 months or who earlier had been randomly assigned to the same study were excluded. Finally, patients were excluded if they had used cholinesterase inhibitors or memantine for less than 3 months or if any change in the dosage had been introduced during the previous 2 weeks; cyclosporin or strong analgesics like opioids, such as codeines and all morphines; carisoprodol; antiepileptics or antipsychotics; monoamine oxidase inhibitors or lithium.
Participants were allowed to take 1 g of paracetamol 3-4 times a day. Those who used a psychotropic drug were not allowed to make any dose changes within 2 weeks before and throughout the study, nor was the commencement of treatment with new psychotropic medication (except rescue medication with haloperidol) permitted during this period.
Intervention
Patients were randomly assigned in blocks of 4 to treatment with 300-900 mg OXC (Trileptal , Novartis) per day or a placebo in a 1: 1 ratio (for study assignment, see fig. 1 ). Individualized dosing was chosen in view of the limited published data regarding the safety, tolerability and efficacy of this agent for this population, similar to the study of Tariot et al. [25] . Treatment started with 75 mg in the morning and 225 mg in the evening. Doses were increased stepwise, reaching a total daily dose of 900 mg OXC after 3 weeks. In this quite old and frail population, we followed the principles of geriatric medicine and reduced the dose to half of the possible highest dose. Our clinical experience using OXC in old patients led us to use 900 mg as the maximum dose. The highest well-tolerated dose for each patient was maintained for the rest of the study. Dose adjustments were permitted if there were adverse events or other problems. All personnel involved in conducting the study remained unaware of the treatment groups until all the data had been retrieved, double data entry had been checked, a blind review had been performed, and the report of the analysis had been written.
Outcomes
Efficacy assessments were made at baseline and at weeks 2, 4, 8 and 12. The primary efficacy variable was change in the agitation and aggression subscore of NPI-NH. This subscore is the product of intensity scores (0-3 points) and frequency scores (0-4 points), and ranges from 0 to 12, with higher scores indicating severer symptoms. Secondary clinical outcome variables were change in agitation, as measured by the Norwegian version of the Brief Agitation Rating Scale (BARS) [29] , and change in the burden of care, as measured by the NPI-NH. The Norwegian version of BARS is a 10-item scale, for which each score ranges from 1 (never) to 7 (more times a day); therefore, the total score ranges from 10 to 70, with higher scores indicating more frequent symptoms of agitation [30] .
Specialized registered nurses from departments of geriatric psychiatry or geriatrics carried out the assessments by interviewing the patients' primary professional caregivers. In addition, the study nurses always interviewed the same caregiver. Through this, we tried to increase the test-retest reliability. Prior to the study they attended a 1-day training course in the use of NPI-NH and BARS. The Norwegian version of NPI-NH was tested for reliability and validity and found to be excellent [31] .
Safety evaluations included recording of adverse events, laboratory tests conducted at screening and in weeks 2 and 6, electrocardiography obtained at screening and in week 2, and measurements of blood pressure and pulse rates. Adverse events were coded with the use of a standard glossary related to body systems. A central laboratory conducted all of the laboratory tests; if the results were out of the normal range, a safety manager warned the investigators at the various study sites by telephone. Concomitant medication and dose changes were recorded.
Statistical Analysis
The sample size necessary to demonstrate a statistically significant difference between the 2 treatments was determined prior to beginning the study. The standard deviation of the subscale for aggression and agitation in NPI-NH was estimated to be 1.8. Based on a 2-sided t test with an assumed difference between the 2 treatments of 1.2 on the aggression and agitation subscale in NPI-NH (for the active drug an estimated reduction of 30% and for the placebo an estimated reduction of 15%), a total of 78 randomized patients would be needed to detect this difference with 80% power. Adjusting for possible dropouts, we decided to enroll 100 patients in the study. All patients who received at least 1 dose of the study medication were included in the primary and safety population and made up the intention-to-treat population. Patients who dropped out were regarded as lost to follow-up, but the information on them that had already been collected was used in the analysis. A last-observation-carried-forward approach was used for the imputation of missing values. Data were described as means and SD; for variables that were not normally distributed, we used the medians and ranges. The differences between the treatment groups for primary and secondary variables were analyzed by a repeated-measures model with an autoregressive covariance structure, including the baseline value as a covariate in the model. The normal distribution assumption was assessed using QQ plots and histograms of residuals. Statistical analyses were performed with SAS software, version 9.1.3 (SAS Institute). An alternative analysis was performed, where the data were treated as categorical and nonparametric methods were used. However, the results were very similar to the results achieved when using the more 'classical approach'. fig. 1 ). There were no significant differences in demographic and baseline data between the 2 groups ( table 1 ). A history of stroke was prevalent in 27.5% of the placebo group and 28.8% of the OXC group, and a history of psychiatric disorders was prevalent in 15.7 and 15.4% of the placebo and OXC group. Fifty-two patients were assigned to receive OXC, and 51 to receive the placebo. A total of 83 patients (80.5%) completed the study according to the protocol, and thereby formed the per protocol population. Of the 20 patients whose participation in the study was discontinued, due to adverse events or because consent was withdrawn, 5 (4.9%) belonged to the placebo group and 15 (14.6%) to the OXC group. The mean trial drug dose reached, including the titration period, was 712 mg (SD 82.3) for placebo and 536.6 (SD 158.0) for OXC.
Results
Patients
The first patient was randomly assigned in September 2005 and recruitment was completed in June 2006. A total of 168 patients underwent screening, and 103 were randomly assigned and received at least 1 dose of medication (
Outcomes
After 8 weeks, no significant differences were found between the 2 groups for any of the primary and secondary outcome measures ( table 2 ; fig. 2 ), regardless of whether we analyzed the intention-to-treat or per protocol population. For all outcome variables, the subjects in the OXC group generally performed better than those in the placebo group. This was especially the case for the changes measured by means of the BARS. For this measure, there was a trend favoring the OXC group (p = 0.07; table 2 ; fig. 2 b) . After 8 weeks, 36.3% of patients treated with placebo had a reduction (compared to baseline) in the agitation and aggression subscore on NPI-NH compared to 39.0% of the patients in the OXC group. There was no significant difference in haloperidol use as rescue medication between the groups (p = 0.26).
Adverse Events
The number of patients with some adverse events was 39 (75%) in the OXC group and 24 (47%) in the placebo group (p ! 0.01). During the study, 71 adverse events oc- 1 Higher scores indicate increased burden on the staff. 2 A score of ≥6 was needed for inclusion. 3 A score of 7 indicates no agitation; a score of 70 indicates heavy agitation. 4 Higher scores indicate better mental functioning.
curred in the OXC group, of which 23 were mild, 44 moderate and 4 severe. The corresponding figures for the placebo group were 31 in total and 15, 15 and 1, when graded according to severity. In the OXC group, 54 (76%) of the adverse events were evaluated as related to treatment, whereas the corresponding figure for the placebo group was 16 (51%; p ! 0.001). Three of the 4 serious adverse events in the OXC group were considered to be related to the treatment, while there were none in the placebo group. Sedation and its consequences were the main reason for nearly all of the adverse events. The most common adverse events are listed in table 3 .
Discussion
This randomized placebo-controlled trial examined the effect of OXC in the treatment of agitation and aggression in patients with dementia. This study was neither designed nor financed by the pharmaceutical industry. Mood stabilizers valproate and carbamazepine have been investigated in 4 and 2 randomized controlled trials, respectively. Only 1 study with carbamazepine showed a statistically significant effect. Our data failed to prove that OXC is efficacious in treating aggression and agitation in patients with dementia. We observed a trend, however, that patients randomly assigned to OXC performed better than those assigned to the placebo (p = 0.07), as measured by the BARS.
Poor statistical power may be one reason why we could not prove that OXC was efficacious. Our power calculation, done prior to the study, was based on a much larger estimated difference between the groups. The placebo group showed a 36.3% reduction in agitation and aggression score on the NPI-NH compared to 39.0% in the OXC group, but our estimates were 15 and 30% for the 2 groups. In order to detect a significant effect with such a small difference, the study would have required enrollment of 232 patients. Other short-term studies in similar populations have reported high placebo response rates, ranging from 21 to 58% [15, 16, 20] . A high placebo effect may be caused by the disease's naturally fluctuat- Values presented as means with SD in parentheses. Scores for aggression/agitation sub-score of the NPI-NH range from 0 to 12, with higher scores indicating a more severe state, and decreases in scores indicate improvement. Scores for the BARS range from 7 to 70, with a score of 7 indicating no agitation, and a score of 70 indicating heavy agitation. Scores of the NPI-NH total score burden range from 0 to 60, with higher scores indicating increased burden on the staff. Scores for the NPI-NH aggression/agitation score burden range from 0 to 5, where a score of 0 indicates no burden and 5 indicates a serious burden on the staff.
The assumption of normal residuals was assessed using QQ plots and histograms, and we found that the assumption was not violated. 1 Estimated difference between the groups over the whole treatment period (assessed at weeks 2, 4, and 8).
ing course or by the Hawthorn effect, that is, people being observed in a research context tend to behave differently than they would otherwise [32] . Indirectly, a high placebo effect may also indicate that approaches other than psychotropic drugs, especially increased care, can improve behavior in patients with dementia in nursing homes. The choice of patient population could also influence the placebo effect. In our study the patients had high scores for symptoms such as agitation and aggression at baseline ( table 1 ) ; thus, increasing the probability of a lower score later (i.e. regression toward the mean phenomenon) [33] .
Another aspect that ought to be considered is the sensitivity of the outcome measures. Items 1-4 in the agitation and aggression subscale of NPI-NH are directed to a passive form of aggression, whereas items 5-8 address active aggression, including an impulsive type of behavior. The form of aggression that causes the most stress for nursing home personnel and other patients is striking out, an impulsive and uncontrolled form of aggression. This type of aggression is often the reason why psychotropic drugs are prescribed. This may be why we found a near statistical significant improvement in favor of the OXC group compared with the placebo group using the BARS as a measure of efficacy. Although BARS seems to capture uncontrolled aggression better than NPI-NH, there is still a need for a more specific instrument that can measure the kind of aggressive behavior that we are most interested in: the impulsive, unexpected, physical form of aggression directed toward caregivers and the other patients in nursing-home wards. In post hoc subanalyses, we found that a high level of aggression (NPI-NH agitation/aggression score 9 or 12) showed a tendency to a better response to the active drug after 4 weeks (p = 0.095), but not after 8 weeks (p = 0.30). We speculate that the treatment with OXC could be effective in demented patients with uncontrolled and impulsive aggression.
Despite the potential variability caused by many sites, we do not believe that there are large differences between the various nursing homes in Norway. Extensive care was taken to select nurses and give them special training so that the inter-rater variability was kept to a minimum. The adverse event profile of OXC in older patients is similar to that in younger patients. No special age-related adverse events have been observed. Safety data from more than 6,600 patients with epilepsy, including elderly patients, support the safe use of OXC [34] . However, clinical practice and a vast majority of clinical studies show that patients with dementia respond differently to psychotropic drugs than the healthy elderly, with those with dementia being more sensitive to side effects. In our trial, the profile of adverse events shows that OXC led to sedation in 25% of the patients ( table 3 ) , a side effect that must be considered as a particular disadvantage for physically and mentally ill patients. Consequently, there was a stronger tendency toward ataxia and falls among this group. In summary, these side effects may lead to serious concerns when using OXC in this population.
There is a great need for further research to enhance our understanding of the neurobiological changes in agitation and aggression in dementia, which might lead to more adequate drug therapy, if that is the best treatment strategy. This and other drug studies have shown that the placebo response in patients with dementia is high, which highlights the importance of psychosocial, environmental and educational strategies in treating behavioral and psychological symptoms of dementia.
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